Best US Health Care Stocks to Invest In
AI-curated Health Care stock ideas for the US market, each with a buy signal, future-value target and a short thesis. Refreshed every weekday from end-of-day data.
20 picks · prices as of close 2026-10-27
BioMarin Pharmaceutical Inc.
Rare-disease portfolio and strong analyst upside support attractive six-to-twelve-month appreciation potential.
▸Strong Buy consensus and repeated analyst Buy ratings.
Ionis Pharmaceuticals, Inc.
Late-stage pipeline optionality and substantial consensus upside create a compelling biotechnology setup.
▸Analyst Buy ratings and high consensus price target.
Boston Scientific Corporation
Structural medtech growth and procedure recovery provide durable earnings momentum with analyst support.
▸Strong Buy consensus and recent analyst Buy reiteration.
Stryker Corporation
Robotic surgery leadership and resilient procedure demand support premium forward growth.
▸Strong Buy consensus and Barclays Buy rating.
UnitedHealth Group Incorporated
Depressed valuation and multiple recent target increases offer recovery potential in managed care.
▸Mizuho and Piper Sandler raised price targets.
Humana Inc.
Medicare Advantage reset expectations and upgraded analyst sentiment could drive a valuation rebound.
▸Cantor upgraded to Overweight with a sharply higher target.
Bristol-Myers Squibb Company
Defensive cash flow, pipeline catalysts, and moderate valuation provide balanced upside.
▸Barclays and JPMorgan maintained Buy ratings.
Hinge Health, Inc.
Digital musculoskeletal care growth and rising targets offer high-growth upside with execution risk.
▸KeyCorp raised its Overweight target to $140.
Haemonetics Corporation
Blood-management demand and favorable analyst coverage support continued operational momentum.
▸Multiple analysts maintained Buy ratings with targets above market.
Alignment Healthcare, Inc.
Medicare Advantage growth and improving sentiment provide substantial small-cap healthcare upside.
▸Analyst coverage identifies improving fundamentals and upside potential.
Cryoport, Inc.
Cell and gene therapy logistics recovery offers significant operating leverage and catalyst potential.
▸BTIG reiterated Buy and raised target to $26.
HealthEquity, Inc.
Health savings account adoption supports recurring growth and defensive healthcare technology exposure.
▸BTIG reiterated Buy with a $115 target.
Becton, Dickinson and Company
Recurring medical-device demand and renewed analyst optimism support dependable forward returns.
▸Recent upgrades and higher targets indicate improving institutional confidence.
Absci Corporation
AI-enabled drug discovery creates asymmetric upside around partnerships and clinical milestones.
▸KeyCorp maintained Overweight and raised its target.
Merck & Co., Inc.
Large-scale cash generation and pipeline diversification provide defensive value despite patent risks.
▸Valuation support and pipeline catalysts attract institutional interest.
Eli Lilly and Company
Obesity and diabetes medicine leadership remains a powerful earnings and momentum catalyst.
▸Strong momentum and raised analyst targets support continued accumulation.
Johnson & Johnson
Diversified pharmaceuticals and medtech provide resilient compounding with defensive downside protection.
▸Institutional-quality defensive earnings and healthcare sector positioning.
Intuitive Surgical, Inc.
Robotic surgery adoption and recurring instruments revenue support durable long-term momentum.
▸Procedure growth and positive medtech momentum remain intact.
Vertex Pharmaceuticals Incorporated
Rare-disease dominance and new product launches support high-quality earnings durability.
▸Pipeline launches and strong institutional-quality fundamentals.
Regeneron Pharmaceuticals, Inc.
Immunology and ophthalmology franchises provide strong cash flow and pipeline optionality.
▸Pipeline catalysts and durable specialty-pharma demand.